AI in Genomics Market Size, Share & Trends Analysis Report by Component (Software, Hardware, Services), Technology, Genomics Workflow, Deployment Mode, Data Type, Therapeutic Area, Application, End User, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2026–2035
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
AI in Genomics market Size, Share, and Growth
The global AI in genomics market is witnessing strong growth, valued at USD 0.6 billion in 2025 and projected to reach USD 6.5 billion by 2035, expanding at a CAGR of 27.8% during the forecast period. The AI in Genomics market is fastest growing in Asia Pacific due to increasing investments in genomic research, expanding precision medicine initiatives, growing adoption of AI technologies, and rising government support for biotechnology and healthcare innovation.
Rami Mehio, senior vice president and general manager of BioInsight at Illumina, said, “These advances expand the scope of biological questions researchers can address across germline, oncology, and multiomic applications while maintaining the speed, scale, and operational consistency expected from DRAGEN”
The AI in genomics market is witnessing strong growth as healthcare organizations, research institutes, Healthcare institutions, research centers, and biopharmaceutical companies are increasingly turning to AI for its potential to boost genomic analysis speed, biomarker identification, precision medicine, and drug discovery, driving significant growth in the AI in genomics market. AI algorithms also drastically cut down on the time needed to understand vast amounts of genomic data, increase the accuracy of identifying variants, and contribute to quicker clinical decision-making in oncology and rare disease and inherited disorders.
The rising investments in cloud-based genomic platforms, growing availability of next generation sequencing (NGS) data, and an increasing number of multi-omics research studies are further contributing to market adoption. For example, Illumina launched DRAGEN v4.5 in January 2026, with new features to support the use of AI for secondary genomic analysis, delivering both increased speed and accuracy for clinical and research use. Moreover, in March 2026, Tempus AI enhanced its AI-driven precision medicine platform with the incorporation of multimodal genomic and clinical data to boost biomarker discovery and personalized treatment recommendations within oncology.
Adjacent market opportunities for the AI in genomics market include AI in Drug Discovery, Precision Medicine, Next-Generation Sequencing (NGS), Clinical Decision Support Systems, and Multi-omics Data Analytics. The convergence of these markets is accelerating genomic research, personalized healthcare, biomarker identification, and AI-enabled therapeutic development across clinical and pharmaceutical applications.
AI in Genomics market Dynamics and Trends
Driver: Rising Demand for Faster Genomic Interpretation and Variant Identification
- The expansion of next generation sequencing has produced enormous amounts of genomic information, and there is an increasing need for the rapid and accurate interpretation of genetic variants. AI can automate the analysis process, focus on clinically relevant mutations and save hours in transforming the sequencing information into actionable data for scientists and clinicians.
- The use of AI for genomic interpretation enhances diagnostic precision, contributes to precision medicine, and expedites disease risk assessment, biomarker identification, and treatment decisions. The use of AI-driven variant analysis platforms is growing, especially as genomics becomes a key factor in clinical decisions.
- Adoption of AI in genomics is growing rapidly due to faster genomic interpretation, better clinical outcomes, and greater adoption of AI genomic interpretation across the globe.
Restraint: Limited Availability of High-Quality Annotated Genomic Datasets Restrains Artificial Intelligence Performance
- Reliable AI models rely on extensive, diverse, and well-annotated genomic data sets for accurate predictions and meaningful clinical insights. Still, genomic information is typically dispersed among healthcare organizations, research institutes, and biobanks, and the methods and standards of annotation are inconsistent, and the approaches to sequencing are different and the degree of interoperability between platforms is limited.
- Limited data access, lack of diversity in data, and strict data privacy policies also limit AI model training and validation. Such challenges limit the generalizability of algorithms and make development more difficult, and slow the adoption of AI genomics solutions in clinical and research applications.
- The lack of access to standardized and high-quality genomic data remains a major hurdle for scalability and clinical use of AI in genomics.
Opportunity: Growing Integration of Multi-Omics Artificial Intelligence Platforms Accelerates Precision Therapeutic Discovery Globally
- The incorporation of artificial intelligence into the study of genomics, transcriptomics, proteomics, metabolomics and clinical data is opening up new opportunities to analyse diseases in a much more complex way and discover more precise therapeutics. Multi-omics platforms powered by AI help researchers uncover intricate biological dynamics, uncover novel biomarkers and enhance the stratification of patients for personalized medicine.
- The increasing investment in multi-omics research by pharmaceutical companies and research institutions will drive the demand for AI-driven analytics platforms to further speed up drug development, improve personalized medicine, and catalyze innovation.
- In May 2026, DNAnexus launched a new multi-omics version of its AI-driven precision health platform for integrated analysis of genomic, transcriptomic, imaging and clinical data, to drive biomarker discovery, AI model development and precision therapeutic discovery.
- AI-powered multi-omics integration is creating new avenues for growth in precision medicine and next-generation therapeutic discovery.
Key Trend: Rapid Adoption of Generative Artificial Intelligence for Automated Genomic Research Workflows
- Genomic research is undergoing a revolution with the advent of generative AI, which is revolutionizing the way scientists interpret data, analyze variants, search for literature, and generate clinical reports. The advanced AI models enable researchers to leverage complex genomic data in a more efficient manner, automate manual tasks, and expedite the discovery of biomarkers, disease understanding, and precision medicine studies.
- Additionally, the use of generative AI is enhancing collaboration between research institutes and biopharmaceutical firms, allowing for the quicker extraction of knowledge, hypothesis generation, and decision-making based on data throughout genomic research workflows.
- Genomics announced in June 2026 the launch of Mystra AI, a conversational generative AI solution for automating genomic analysis and drug target discovery, powered by the world's largest genotype-phenotype database, helping researchers to speed up precision medicine and genomic research workflows.
- The widespread adoption of generative AI is driving more efficient genomic research, improved scientific discoveries and precision medicine globally.
AI in Genomics Market Analysis and Segmental Data
Machine Learning (ML) Dominate Global AI in Genomics Market
- Genomic research is undergoing a revolution with the advent of generative AI, which is revolutionizing the way scientists interpret data, analyze variants, search for literature, and generate clinical reports. The advanced AI models enable researchers to leverage complex genomic data in a more efficient manner, automate manual tasks, and expedite the discovery of biomarkers, disease understanding, and precision medicine studies.
- Additionally, the use of generative AI is enhancing collaboration between research institutes and biopharmaceutical firms, allowing for the quicker extraction of knowledge, hypothesis generation, and decision-making based on data throughout genomic research workflows.
- Genomics announced in June 2026 the launch of Mystra AI, a conversational generative AI solution for automating genomic analysis and drug target discovery, powered by the world's largest genotype-phenotype database, helping researchers to speed up precision medicine and genomic research workflows.
- The widespread adoption of generative AI is driving more efficient genomic research, improved scientific discoveries and precision medicine globally.
North America Leads Global AI in Genomics Market Demand
- North America dominates the AI in genomics market with its early adoption of artificial intelligence in life sciences, advanced healthcare infrastructure, and well-established genomics research ecosystem. The region has huge investments in sequencing, precision medicine, and AI-powered bioinformatics, allowing for quicker analysis of the genome and clinical applications.
- Leading biotechnology firms, genomic research centres and AI technology firms add to regional leadership. The genomics innovation and commercialization continues to be fueled by strong government investments, growing partnerships between healthcare providers and research institutions, and the rise of cloud-based genomics analytics platforms.
- North America continues to be the world leader in AI-powered genomics innovation, driving precision medicine and next-generation genomic research.
AI in Genomics Market Ecosystem
The global AI in genomics market is consolidated, led by key players such as Illumina, Inc., Thermo Fisher Scientific Inc., Microsoft Corporation, Alphabet Inc., and NVIDIA Corporation. These companies strengthen their market position through advancements in AI, machine learning, genomic sequencing, bioinformatics, and cloud-based analytics. Their competitive advantage is supported by strategic collaborations with research institutions, healthcare providers, and pharmaceutical companies, alongside continuous investments in precision medicine and genomic innovation.
The value chain begins with genomic data generation through sequencing technologies, reagents, and computational infrastructure, followed by AI model development, bioinformatics analysis, variant interpretation, and clinical validation. AI-powered platforms support genome analysis, biomarker discovery, drug development, and precision medicine. Ongoing software upgrades, cloud analytics, and technical support ensure accurate and scalable genomic insights.
The market has moderate-to-high entry barriers due to high sequencing costs, advanced AI and bioinformatics expertise, stringent regulatory requirements, and significant R&D investments. Leading companies maintain their position through proprietary sequencing platforms, AI-driven analytics, extensive genomic databases, and strong research partnerships.
Recent Development and Strategic Overview
- In September 2025, BGI Genomics launched its AI-powered i99 health management platform and GeneT Agent, integrating genomic, multi-omics, imaging, and lifestyle data to enhance disease prevention, genetic interpretation, and clinical decision-making, while accelerating AI-driven precision healthcare and genomic diagnostics.
- In May 2026, Helio Genomics partnered with Syneos Health to accelerate U.S. adoption of HelioLiver, an AI-powered blood test that combines cell-free DNA methylation, protein biomarkers, and patient data using proprietary AI algorithms to enable earlier detection of liver cancer and improve precision diagnostics.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 0.6 Bn |
|
Market Forecast Value in 2035 |
USD 6.5 Bn |
|
Growth Rate (CAGR) |
27.8% |
|
Forecast Period |
2026 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
|
|
||
AI in Genomics Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
AI in Genomics Market, By Component |
|
|
AI in Genomics Market, By Meal Category |
|
|
AI in Genomics Market, By Technology |
|
|
AI in Genomics Market, By Genomics Workflow |
|
|
AI in Genomics Market, By Deployment Mode |
|
|
AI in Genomics Market, By Data Type |
|
|
AI in Genomics Market, By Therapeutic Area |
|
|
AI in Genomics Market, By Application |
|
|
AI in Genomics Market, By End User |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global AI in Genomics Market Outlook
- 2.1.1. AI in Genomics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global AI in Genomics Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. AI-driven genomic data analysis and variant interpretation.
- 4.1.1.2. Growing adoption of precision medicine and multi-omics integration.
- 4.1.1.3. Rising demand for AI-enabled drug discovery and biomarker identification.
- 4.1.2. Restraints
- 4.1.2.1. Limited availability of high-quality annotated genomic datasets.
- 4.1.2.2. Data privacy and regulatory compliance challenges.
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global AI in Genomics Market Demand
- 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global AI in Genomics Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
- 6.2.1. Software
- 6.2.1.1. Genomic Data Analysis Software
- 6.2.1.2. Variant Calling & Interpretation Software
- 6.2.1.3. Genome Annotation Software
- 6.2.1.4. Multi-Omics Analysis Software
- 6.2.1.5. Clinical Decision Support Software
- 6.2.1.6. Drug Discovery & Biomarker Discovery Software
- 6.2.1.7. Bioinformatics Workflow Management Software
- 6.2.1.8. AI Development & Analytics Platforms
- 6.2.1.9. Others
- 6.2.2. Hardware
- 6.2.2.1. High-Performance Computing (HPC) Systems
- 6.2.2.2. GPU & AI Accelerators
- 6.2.2.3. AI Servers
- 6.2.2.4. Genomic Sequencing Instruments
- 6.2.2.5. Data Storage Systems
- 6.2.2.6. Networking Infrastructure
- 6.2.2.7. Laboratory Automation Hardware
- 6.2.2.8. Edge AI Computing Devices
- 6.2.2.9. Others
- 6.2.3. Services
- 6.2.3.1. AI Consulting Services
- 6.2.3.2. Bioinformatics & Genomic Data Analysis Services
- 6.2.3.3. AI Software Integration & Deployment Services
- 6.2.3.4. Cloud & Managed AI Services
- 6.2.3.5. Variant Interpretation Services
- 6.2.3.6. Regulatory & Compliance Services
- 6.2.3.7. Technical Support & Maintenance
- 6.2.3.8. Training & Professional Services
- 6.2.3.9. Others
- 6.2.1. Software
- 7. Global AI in Genomics Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Machine Learning (ML)
- 7.2.2. Deep Learning
- 7.2.3. Natural Language Processing (NLP)
- 7.2.4. Computer Vision
- 7.2.5. Generative AI
- 7.2.6. Reinforcement Learning
- 7.2.7. Explainable AI (XAI)
- 7.2.8. Predictive Analytics
- 7.2.9. Federated Learning
- 7.2.10. Others
- 8. Global AI in Genomics Market Analysis, by Genomics Workflow
- 8.1. Key Segment Analysis
- 8.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Genomics Workflow, 2021-2035
- 8.2.1. Genome Sequencing
- 8.2.2. Variant Calling
- 8.2.3. Genome Assembly
- 8.2.4. Gene Expression Analysis
- 8.2.5. Functional Genomics
- 8.2.6. Epigenomics Analysis
- 8.2.7. Multi-Omics Data Integration
- 8.2.8. Genome Annotation
- 8.2.9. Biomarker Discovery
- 8.2.10. Others
- 9. Global AI in Genomics Market Analysis, by Deployment Mode
- 9.1. Key Segment Analysis
- 9.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
- 9.2.1. Cloud-Based
- 9.2.2. On-Premises
- 9.2.3. Hybrid
- 10. Global AI in Genomics Market Analysis, by Data Type
- 10.1. Key Segment Analysis
- 10.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Data Type, 2021-2035
- 10.2.1. Whole Genome Sequencing (WGS)
- 10.2.2. Whole Exome Sequencing (WES)
- 10.2.3. RNA Sequencing
- 10.2.4. Single-Cell Sequencing
- 10.2.5. DNA Methylation Data
- 10.2.6. Proteomics Data
- 10.2.7. Metabolomics Data
- 10.2.8. Microbiome Data
- 10.2.9. Multi-Omics Data
- 11. Global AI in Genomics Market Analysis, by Therapeutic Area
- 11.1. Key Segment Analysis
- 11.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
- 11.2.1. Oncology
- 11.2.2. Neurology
- 11.2.3. Cardiology
- 11.2.4. Rare Genetic Disorders
- 11.2.5. Infectious Diseases
- 11.2.6. Immunology
- 11.2.7. Metabolic Disorders
- 11.2.8. Reproductive Health
- 11.2.9. Pharmacogenomics
- 11.2.10. Others
- 12. Global AI in Genomics Market Analysis, by Application
- 12.1. Key Segment Analysis
- 12.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
- 12.2.1. Drug Discovery & Development
- 12.2.2. Precision Medicine
- 12.2.3. Clinical Diagnostics
- 12.2.4. Disease Risk Prediction
- 12.2.5. Rare Disease Analysis
- 12.2.6. Oncology Genomics
- 12.2.7. Population Genomics
- 12.2.8. Agricultural Genomics
- 12.2.9. Infectious Disease Genomics
- 12.2.10. Other Applications
- 13. Global AI in Genomics Market Analysis, by End-user
- 13.1. Key Segment Analysis
- 13.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-user, 2021-2035
- 13.2.1. Pharmaceutical & Biotechnology Companies
- 13.2.2. Academic & Research Institutes
- 13.2.3. Hospitals
- 13.2.4. Clinical Laboratories
- 13.2.5. Diagnostic Centers
- 13.2.6. Contract Research Organizations (CROs)
- 13.2.7. Government & Public Health Organizations
- 13.2.8. Agricultural & Food Research Organizations
- 13.2.9. Forensic Laboratories
- 13.2.10. Others
- 14. Global AI in Genomics Market Analysis, by Region
- 14.1. Key Findings
- 14.2. AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 14.2.1. North America
- 14.2.2. Europe
- 14.2.3. Asia Pacific
- 14.2.4. Middle East
- 14.2.5. Africa
- 14.2.6. South America
- 15. North America AI in Genomics Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. North America AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Component
- 15.3.2. Technology
- 15.3.3. Genomics Workflow
- 15.3.4. Deployment Mode
- 15.3.5. Data Type
- 15.3.6. Therapeutic Area
- 15.3.7. Application
- 15.3.8. End User
- 15.3.9. Country
- 15.3.9.1. USA
- 15.3.9.2. Canada
- 15.3.9.3. Mexico
- 15.4. USA AI in Genomics Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Component
- 15.4.3. Technology
- 15.4.4. Genomics Workflow
- 15.4.5. Deployment Mode
- 15.4.6. Data Type
- 15.4.7. Therapeutic Area
- 15.4.8. Application
- 15.4.9. End User
- 15.5. Canada AI in Genomics Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Component
- 15.5.3. Technology
- 15.5.4. Genomics Workflow
- 15.5.5. Deployment Mode
- 15.5.6. Data Type
- 15.5.7. Therapeutic Area
- 15.5.8. Application
- 15.5.9. End User
- 15.6. Mexico AI in Genomics Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Component
- 15.6.3. Technology
- 15.6.4. Genomics Workflow
- 15.6.5. Deployment Mode
- 15.6.6. Data Type
- 15.6.7. Therapeutic Area
- 15.6.8. Application
- 15.6.9. End User
- 16. Europe AI in Genomics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Europe AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Component
- 16.3.2. Technology
- 16.3.3. Genomics Workflow
- 16.3.4. Deployment Mode
- 16.3.5. Data Type
- 16.3.6. Therapeutic Area
- 16.3.7. Application
- 16.3.8. End User
- 16.3.9. Country
- 16.3.9.1. Germany
- 16.3.9.2. United Kingdom
- 16.3.9.3. France
- 16.3.9.4. Italy
- 16.3.9.5. Spain
- 16.3.9.6. Netherlands
- 16.3.9.7. Nordic Countries
- 16.3.9.8. Poland
- 16.3.9.9. Russia & CIS
- 16.3.9.10. Rest of Europe
- 16.4. Germany AI in Genomics Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Component
- 16.4.3. Technology
- 16.4.4. Genomics Workflow
- 16.4.5. Deployment Mode
- 16.4.6. Data Type
- 16.4.7. Therapeutic Area
- 16.4.8. Application
- 16.4.9. End User
- 16.5. United Kingdom AI in Genomics Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Component
- 16.5.3. Technology
- 16.5.4. Genomics Workflow
- 16.5.5. Deployment Mode
- 16.5.6. Data Type
- 16.5.7. Therapeutic Area
- 16.5.8. Application
- 16.5.9. End User
- 16.6. France AI in Genomics Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Component
- 16.6.3. Technology
- 16.6.4. Genomics Workflow
- 16.6.5. Deployment Mode
- 16.6.6. Data Type
- 16.6.7. Therapeutic Area
- 16.6.8. Application
- 16.6.9. End User
- 16.7. Italy AI in Genomics Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Component
- 16.7.3. Technology
- 16.7.4. Genomics Workflow
- 16.7.5. Deployment Mode
- 16.7.6. Data Type
- 16.7.7. Therapeutic Area
- 16.7.8. Application
- 16.7.9. End User
- 16.8. Spain AI in Genomics Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Component
- 16.8.3. Technology
- 16.8.4. Genomics Workflow
- 16.8.5. Deployment Mode
- 16.8.6. Data Type
- 16.8.7. Therapeutic Area
- 16.8.8. Application
- 16.8.9. End User
- 16.9. Netherlands AI in Genomics Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Component
- 16.9.3. Technology
- 16.9.4. Genomics Workflow
- 16.9.5. Deployment Mode
- 16.9.6. Data Type
- 16.9.7. Therapeutic Area
- 16.9.8. Application
- 16.9.9. End User
- 16.10. Nordic Countries AI in Genomics Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Component
- 16.10.3. Technology
- 16.10.4. Genomics Workflow
- 16.10.5. Deployment Mode
- 16.10.6. Data Type
- 16.10.7. Therapeutic Area
- 16.10.8. Application
- 16.10.9. End User
- 16.11. Poland AI in Genomics Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Component
- 16.11.3. Technology
- 16.11.4. Genomics Workflow
- 16.11.5. Deployment Mode
- 16.11.6. Data Type
- 16.11.7. Therapeutic Area
- 16.11.8. Application
- 16.11.9. End User
- 16.12. Russia & CIS AI in Genomics Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Component
- 16.12.3. Technology
- 16.12.4. Genomics Workflow
- 16.12.5. Deployment Mode
- 16.12.6. Data Type
- 16.12.7. Therapeutic Area
- 16.12.8. Application
- 16.12.9. End User
- 16.13. Rest of Europe AI in Genomics Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Component
- 16.13.3. Technology
- 16.13.4. Genomics Workflow
- 16.13.5. Deployment Mode
- 16.13.6. Data Type
- 16.13.7. Therapeutic Area
- 16.13.8. Application
- 16.13.9. End User
- 17. Asia Pacific AI in Genomics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Asia Pacific AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Component
- 17.3.2. Technology
- 17.3.3. Genomics Workflow
- 17.3.4. Deployment Mode
- 17.3.5. Data Type
- 17.3.6. Therapeutic Area
- 17.3.7. Application
- 17.3.8. End User
- 17.3.9. Country
- 17.3.9.1. China
- 17.3.9.2. India
- 17.3.9.3. Japan
- 17.3.9.4. South Korea
- 17.3.9.5. Australia and New Zealand
- 17.3.9.6. Indonesia
- 17.3.9.7. Malaysia
- 17.3.9.8. Thailand
- 17.3.9.9. Vietnam
- 17.3.9.10. Rest of Asia Pacific
- 17.4. China AI in Genomics Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Component
- 17.4.3. Technology
- 17.4.4. Genomics Workflow
- 17.4.5. Deployment Mode
- 17.4.6. Data Type
- 17.4.7. Therapeutic Area
- 17.4.8. Application
- 17.4.9. End User
- 17.5. India AI in Genomics Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Component
- 17.5.3. Technology
- 17.5.4. Genomics Workflow
- 17.5.5. Deployment Mode
- 17.5.6. Data Type
- 17.5.7. Therapeutic Area
- 17.5.8. Application
- 17.5.9. End User
- 17.6. Japan AI in Genomics Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Component
- 17.6.3. Technology
- 17.6.4. Genomics Workflow
- 17.6.5. Deployment Mode
- 17.6.6. Data Type
- 17.6.7. Therapeutic Area
- 17.6.8. Application
- 17.6.9. End User
- 17.7. South Korea AI in Genomics Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Component
- 17.7.3. Technology
- 17.7.4. Genomics Workflow
- 17.7.5. Deployment Mode
- 17.7.6. Data Type
- 17.7.7. Therapeutic Area
- 17.7.8. Application
- 17.7.9. End User
- 17.8. Australia and New Zealand AI in Genomics Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Component
- 17.8.3. Technology
- 17.8.4. Genomics Workflow
- 17.8.5. Deployment Mode
- 17.8.6. Data Type
- 17.8.7. Therapeutic Area
- 17.8.8. Application
- 17.8.9. End User
- 17.9. Indonesia AI in Genomics Market
- 17.9.1. Country Segmental Analysis
- 17.9.2. Component
- 17.9.3. Technology
- 17.9.4. Genomics Workflow
- 17.9.5. Deployment Mode
- 17.9.6. Data Type
- 17.9.7. Therapeutic Area
- 17.9.8. Application
- 17.9.9. End User
- 17.10. Malaysia AI in Genomics Market
- 17.10.1. Country Segmental Analysis
- 17.10.2. Component
- 17.10.3. Technology
- 17.10.4. Genomics Workflow
- 17.10.5. Deployment Mode
- 17.10.6. Data Type
- 17.10.7. Therapeutic Area
- 17.10.8. Application
- 17.10.9. End User
- 17.11. Thailand AI in Genomics Market
- 17.11.1. Country Segmental Analysis
- 17.11.2. Component
- 17.11.3. Technology
- 17.11.4. Genomics Workflow
- 17.11.5. Deployment Mode
- 17.11.6. Data Type
- 17.11.7. Therapeutic Area
- 17.11.8. Application
- 17.11.9. End User
- 17.12. Vietnam AI in Genomics Market
- 17.12.1. Country Segmental Analysis
- 17.12.2. Component
- 17.12.3. Technology
- 17.12.4. Genomics Workflow
- 17.12.5. Deployment Mode
- 17.12.6. Data Type
- 17.12.7. Therapeutic Area
- 17.12.8. Application
- 17.12.9. End User
- 17.13. Rest of Asia Pacific AI in Genomics Market
- 17.13.1. Country Segmental Analysis
- 17.13.2. Component
- 17.13.3. Technology
- 17.13.4. Genomics Workflow
- 17.13.5. Deployment Mode
- 17.13.6. Data Type
- 17.13.7. Therapeutic Area
- 17.13.8. Application
- 17.13.9. End User
- 18. Middle East AI in Genomics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Middle East AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Component
- 18.3.2. Technology
- 18.3.3. Genomics Workflow
- 18.3.4. Deployment Mode
- 18.3.5. Data Type
- 18.3.6. Therapeutic Area
- 18.3.7. Application
- 18.3.8. End User
- 18.3.9. Country
- 18.3.9.1. Turkey
- 18.3.9.2. UAE
- 18.3.9.3. Saudi Arabia
- 18.3.9.4. Israel
- 18.3.9.5. Rest of Middle East
- 18.4. Turkey AI in Genomics Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Component
- 18.4.3. Technology
- 18.4.4. Genomics Workflow
- 18.4.5. Deployment Mode
- 18.4.6. Data Type
- 18.4.7. Therapeutic Area
- 18.4.8. Application
- 18.4.9. End User
- 18.5. UAE AI in Genomics Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Component
- 18.5.3. Technology
- 18.5.4. Genomics Workflow
- 18.5.5. Deployment Mode
- 18.5.6. Data Type
- 18.5.7. Therapeutic Area
- 18.5.8. Application
- 18.5.9. End User
- 18.6. Saudi Arabia AI in Genomics Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Component
- 18.6.3. Technology
- 18.6.4. Genomics Workflow
- 18.6.5. Deployment Mode
- 18.6.6. Data Type
- 18.6.7. Therapeutic Area
- 18.6.8. Application
- 18.6.9. End User
- 18.7. Israel AI in Genomics Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Component
- 18.7.3. Technology
- 18.7.4. Genomics Workflow
- 18.7.5. Deployment Mode
- 18.7.6. Data Type
- 18.7.7. Therapeutic Area
- 18.7.8. Application
- 18.7.9. End User
- 18.8. Rest of Middle East AI in Genomics Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Component
- 18.8.3. Technology
- 18.8.4. Genomics Workflow
- 18.8.5. Deployment Mode
- 18.8.6. Data Type
- 18.8.7. Therapeutic Area
- 18.8.8. Application
- 18.8.9. End User
- 19. Africa AI in Genomics Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Africa AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Component
- 19.3.2. Technology
- 19.3.3. Genomics Workflow
- 19.3.4. Deployment Mode
- 19.3.5. Data Type
- 19.3.6. Therapeutic Area
- 19.3.7. Application
- 19.3.8. End User
- 19.3.9. Country
- 19.3.9.1. South Africa
- 19.3.9.2. Egypt
- 19.3.9.3. Nigeria
- 19.3.9.4. Algeria
- 19.3.9.5. Rest of Africa
- 19.4. South Africa AI in Genomics Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Component
- 19.4.3. Technology
- 19.4.4. Genomics Workflow
- 19.4.5. Deployment Mode
- 19.4.6. Data Type
- 19.4.7. Therapeutic Area
- 19.4.8. Application
- 19.4.9. End User
- 19.5. Egypt AI in Genomics Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Component
- 19.5.3. Technology
- 19.5.4. Genomics Workflow
- 19.5.5. Deployment Mode
- 19.5.6. Data Type
- 19.5.7. Therapeutic Area
- 19.5.8. Application
- 19.5.9. End User
- 19.6. Nigeria AI in Genomics Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Component
- 19.6.3. Technology
- 19.6.4. Genomics Workflow
- 19.6.5. Deployment Mode
- 19.6.6. Data Type
- 19.6.7. Therapeutic Area
- 19.6.8. Application
- 19.6.9. End User
- 19.7. Algeria AI in Genomics Market
- 19.7.1. Country Segmental Analysis
- 19.7.2. Component
- 19.7.3. Technology
- 19.7.4. Genomics Workflow
- 19.7.5. Deployment Mode
- 19.7.6. Data Type
- 19.7.7. Therapeutic Area
- 19.7.8. Application
- 19.7.9. End User
- 19.8. Rest of Africa AI in Genomics Market
- 19.8.1. Country Segmental Analysis
- 19.8.2. Component
- 19.8.3. Technology
- 19.8.4. Genomics Workflow
- 19.8.5. Deployment Mode
- 19.8.6. Data Type
- 19.8.7. Therapeutic Area
- 19.8.8. Application
- 19.8.9. End User
- 20. South America AI in Genomics Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. South America AI in Genomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 20.3.1. Component
- 20.3.2. Technology
- 20.3.3. Genomics Workflow
- 20.3.4. Deployment Mode
- 20.3.5. Data Type
- 20.3.6. Therapeutic Area
- 20.3.7. Application
- 20.3.8. End User
- 20.3.9. Country
- 20.3.9.1. Brazil
- 20.3.9.2. Argentina
- 20.3.9.3. Rest of South America
- 20.4. Brazil AI in Genomics Market
- 20.4.1. Country Segmental Analysis
- 20.4.2. Component
- 20.4.3. Technology
- 20.4.4. Genomics Workflow
- 20.4.5. Deployment Mode
- 20.4.6. Data Type
- 20.4.7. Therapeutic Area
- 20.4.8. Application
- 20.4.9. End User
- 20.5. Argentina AI in Genomics Market
- 20.5.1. Country Segmental Analysis
- 20.5.2. Component
- 20.5.3. Technology
- 20.5.4. Genomics Workflow
- 20.5.5. Deployment Mode
- 20.5.6. Data Type
- 20.5.7. Therapeutic Area
- 20.5.8. Application
- 20.5.9. End User
- 20.6. Rest of South America AI in Genomics Market
- 20.6.1. Country Segmental Analysis
- 20.6.2. Component
- 20.6.3. Technology
- 20.6.4. Genomics Workflow
- 20.6.5. Deployment Mode
- 20.6.6. Data Type
- 20.6.7. Therapeutic Area
- 20.6.8. Application
- 20.6.9. End User
- 21. Key Players/ Company Profile
- 21.1. Alphabet Inc.
- 21.1.1. Company Details/ Overview
- 21.1.2. Company Financials
- 21.1.3. Key Customers and Competitors
- 21.1.4. Business/ Industry Portfolio
- 21.1.5. Product Portfolio/ Specification Details
- 21.1.6. Pricing Data
- 21.1.7. Strategic Overview
- 21.1.8. Recent Developments
- 21.2. Deep Genomics Incorporated
- 21.3. DNAnexus, Inc.
- 21.4. Fabric Genomics, Inc.
- 21.5. Illumina, Inc.
- 21.6. Microsoft Corporation
- 21.7. NVIDIA Corporation
- 21.8. Tempus AI, Inc.
- 21.9. Thermo Fisher Scientific Inc.
- 21.10. Other Key Players
- 21.1. Alphabet Inc.
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation